Daewoong Pharmaceutical Rises 2.59% Amid Uptrend in Biosimilar (Generic Biopharmaceutical) Theme

On the 31st, the biosimilar (generic biopharmaceutical) theme showed strength by rising 3.24% compared to the previous day, while Daewoong Pharmaceutical, a related stock drawing attention, surged 2.59% from the previous day. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

[Graph] Price changes of major stocks in the biosimilar (generic biopharmaceutical) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Daewoong Pharmaceutical's quant financial score was 33.32 points, ranking 10th in quant financial ranking within the biosimilar (generic biopharmaceutical) theme. This can be interpreted as Daewoong Pharmaceutical having relatively low investment attractiveness from a financial perspective. On the other hand, Dong-A ST ranked first in quant financial ranking with higher stability and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the robo algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.